OBJECTIVE: Intravenous immunoglobulin therapy has been proposed as an advanced treatment for sepsis. Yet, its benefit remains unclear and the mechanism of action is poorly understood. One key mediator in the development of sepsis is high mobility group box 1 (HMGB1). Therefore, we examined the serum and lung tissue levels of HMGB1 in a rat model of sepsis. DESIGN AND SETTING: Prospective controlled animal study in a university laboratory. MATERIALS: Rats received either cecal ligation and puncture-induced sepsis or had additional intravenous immunoglobulin treatment in boluses of 100, 300, or 1,000 mg/kg. MEASUREMENTS AND RESULTS: After induction of sepsis and respective treatment conditions, histopathology, wet/dry weight ratios, and signaling molecules were examined in pulmonary tissue. Serum and pulmonary levels of cytokine and HMGB1 were measured. High dose intravenous immunoglobulin (1,000 mg/kg)-treated animals demonstrated significantly improved survival and pulmonary histopathology compared to the control rats. Serum and pulmonary HMGB1 levels were lower over time among intravenous immunoglobulin-treated animals. Furthermore, administration of intravenous immunoglobulin resulted in inhibition of NF-kappaB activity. CONCLUSIONS: High-dose intravenous immunoglobulin decreased the mortality and pulmonary pathology in a rat model of sepsis. A significant reduction in HMGB1 levels was also observed, which may be mediated by inhibition of inflammation and NF-kappaB. DESCRIPTOR: 23. Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI): experimental models.
OBJECTIVE: Intravenous immunoglobulin therapy has been proposed as an advanced treatment for sepsis. Yet, its benefit remains unclear and the mechanism of action is poorly understood. One key mediator in the development of sepsis is high mobility group box 1 (HMGB1). Therefore, we examined the serum and lung tissue levels of HMGB1 in a rat model of sepsis. DESIGN AND SETTING: Prospective controlled animal study in a university laboratory. MATERIALS: Rats received either cecal ligation and puncture-induced sepsis or had additional intravenous immunoglobulin treatment in boluses of 100, 300, or 1,000 mg/kg. MEASUREMENTS AND RESULTS: After induction of sepsis and respective treatment conditions, histopathology, wet/dry weight ratios, and signaling molecules were examined in pulmonary tissue. Serum and pulmonary levels of cytokine and HMGB1 were measured. High dose intravenous immunoglobulin (1,000 mg/kg)-treated animals demonstrated significantly improved survival and pulmonary histopathology compared to the control rats. Serum and pulmonary HMGB1 levels were lower over time among intravenous immunoglobulin-treated animals. Furthermore, administration of intravenous immunoglobulin resulted in inhibition of NF-kappaB activity. CONCLUSIONS: High-dose intravenous immunoglobulin decreased the mortality and pulmonary pathology in a rat model of sepsis. A significant reduction in HMGB1 levels was also observed, which may be mediated by inhibition of inflammation and NF-kappaB. DESCRIPTOR: 23. Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI): experimental models.
Authors: H Böhrer; F Qiu; T Zimmermann; Y Zhang; T Jllmer; D Männel; B W Böttiger; D M Stern; R Waldherr; H D Saeger; R Ziegler; A Bierhaus; E Martin; P P Nawroth Journal: J Clin Invest Date: 1997-09-01 Impact factor: 14.808
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker Journal: Intensive Care Med Date: 2006-02-17 Impact factor: 17.440
Authors: Carmen Fiuza; Michael Bustin; Shefali Talwar; Margaret Tropea; Eric Gerstenberger; James H Shelhamer; Anthony F Suffredini Journal: Blood Date: 2002-11-27 Impact factor: 22.113
Authors: Huan Yang; Mahendar Ochani; Jianhua Li; Xiaoling Qiang; Mahira Tanovic; Helena E Harris; Srinivas M Susarla; Luis Ulloa; Hong Wang; Robert DiRaimo; Christopher J Czura; Haichao Wang; Jesse Roth; H Shaw Warren; Mitchell P Fink; Matthew J Fenton; Ulf Andersson; Kevin J Tracey Journal: Proc Natl Acad Sci U S A Date: 2003-12-26 Impact factor: 11.205
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2010-01-28 Impact factor: 17.440